Overview

A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)

Status:
Terminated
Trial end date:
2019-01-16
Target enrollment:
Participant gender:
Summary
This was a multicenter, open-label safety study to determine the dose regimen of SYNT001 (ALXN1830) administered intravenously in participants with pemphigus (vulgaris or foliaceus).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Alexion Pharmaceuticals
Syntimmune, Inc.